First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

#1102

Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.

Aim(s): Assess the efficacy of these combination in mGEP-NEC patients

Materials and methods: We retrospectively evaluated 20 cases of metastatic GEP-NECs classified according to WHO 2010 and treated with cisplatin 25 mg/m2 on days 1-3 or carboplatin 300 mg/m2 on day 1 followed by etoposide 100 mg/m2 on days 1-3, every 21 days.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: IBRAHIM T

Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,

Keywords: GEP-NEC,chemotherapy,